课题基金 / 基金详情

One trillion photoswitchable molecular devices: a molecular foundry to control protein interactions using light

One trillion photoswitchable molecular devices: a molecular foundry to control protein interactions using light
一万亿光可切换分子器件:利用光控制蛋白质相互作用的分子铸造厂
批准号:
2277405
负责人:
金额:
$0.0万
依托单位:
依托单位国家:
英国
项目类别:
Studentship
财政年份:
2019
资助国家:
英国
项目状态:
已结题
起止时间:
2019 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
控制生物或合成系统中(生物)分子相互作用的普遍能力对化学生物学来说是一个巨大的挑战,解决这一问题将对基础生物学、合成生物学和治疗发现产生广泛的影响。生物分子相互作用的光化学控制是解决这一挑战的一种方法,最近引起了人们的强烈兴趣。突出的例子包括从光响应材料到光响应蛋白质结构域,以及可以控制例如微管蛋白聚合从而对光响应的细胞分裂的光开关配体,也被称为光药理学(Trauner和Feringa实验室最近的论文举例说明)。虽然这些例子为利用光信号对生物学进行微创控制的重要性和潜力提供了原理证明,但它们都存在显著的缺点,例如,对基因操作的要求,或者仅适用于单个高度工程化系统的高度定制的设计。在这里,我们建议通过开发第一个发现任何感兴趣的蛋白质的光开关配体的平台来克服现有范例的局限性,从而实现大量的新方法,包括对酶活性、蛋白质-蛋白质相互作用和蛋白质定位的开/关开关。结合前沿的超稳定光开关技术(Fuchter)和万亿个成员的遗传编码环肽文库合成(Walport),我们将生成一个工具包,用于识别可以以两种可切换构型之一与给定蛋白质结合的配体,并展示其在一系列光可切换蛋白质相互作用(Tate)中的应用。此外,这些分子装置的模块化将使它们能够在未来自下而上和自上而下的合成生物学方法中用作组件,提供对细胞或原细胞中蛋白质功能的翻译后控制。该项目将致力于以下目标:1)设计、合成“第一代”合成重氮光开关,并利用灵活的体外翻译将“第一代”合成重氮光开关并入万亿元环肽库,并选择与模型细胞表面蛋白(Cd59)的结合。2)鉴定选择性可切换配体,它可以调节与CD59的结合,并在细胞系统中诱导可切换配体摄取,以响应光诱导的激活。3)扩展通用可切换配体平台,以例证其在GPCR二聚体(FFA2)、可逆细胞捕获和具有可切换桥的多环肽文库中的应用。可行性与任务:该项目建立在合作实验室独特能力的基础上,包括用于万亿元环肽文库RNA显示的灵活的体外翻译技术(Walport),发现超稳定的光开关(Fuchter),以及泰特小组目前ICB CDT学生的创新,包括使用大规模环肽文库筛选发现高亲和力(不可切换)的cd59配体(Bickel;与Bubeck实验室),以及在小分子探测器中引入细胞活性光开关(Kounde;与GSK)。因此,我们拥有了这个项目的物理科学创新将建立在其上的复杂技术,包括经过验证的环肽库、健壮的光开关,以及访问一系列用于测试PhysSci创新的模型系统。该项目直接涉及ICB CDT的核心任务,包括分子相互作用(蛋白质/配体、蛋白质/蛋白质)和将新装置纳入多尺度生物框架,在生物科学和合成生物学方面具有重要的未来应用。
英文摘要
The universal ability to control (bio)molecular interactions in living or synthetic systems is a grand challenge for chemical biology, a solution for which would have wide-ranging implications for basic biology, synthetic biology and therapeutic discovery. Photochemical control of biomolecular interactions is an approach to this challenge which has attracted intense recent interest. Prominent examples range from photoresponsive materials to light-responsive protein domains, and photoswitchable ligands which can control e.g. tubulin polymerization and thus cell division in response to light, also termed photopharmacology (exemplified by recent papers from the Trauner and Feringa labs). Whilst these examples provide proof of principle for the importance and potential of minimally invasive control of biology using light signals, they each suffer from significant disadvantages, for example a requirement for genetic manipulation, or a highly bespoke design which works only for a single highly engineered system. Here we propose to overcome the limitations of existing paradigms by developing the first discovery platform for photoswitchable ligands to any protein of interest, enabling a plethora of new approaches including on/off switches for enzyme activity, protein-protein interactions, and protein localisation. Combining cutting-edge hyperstable photoswitch technology (Fuchter) with trillion-member genetically encoded cyclic peptide library synthesis (Walport) we will generate a toolkit for the identification of ligands which can bind to a given protein in one of two switchable configurations and demonstrate its application to a series of light-switchable protein interactions (Tate). Furthermore, the modularity of these molecular devices will enable their use as a component in future bottom-up and top-down synthetic biology approaches, providing post-translational control over protein function in cells or protocells. The project will address the following Aims: 1) Design, synthesise and incorporate '1st generation' synthetic diazo photoswitches into a trillion-member cyclic peptide library using flexible in vitro translation, and select binders to a model cell surface protein (cd59) . 2) Identify selective switchable ligands which can modulate binding to cd59 and induce switchable ligand uptake in a cellular system in response to light-induced activation. 3) Expand the universal switchable ligand platform to exemplify applications in GPCR dimerisation (FFA2), reversible cell capture, and multicyclic peptide libraries with switchable bridges. Achievability & Remit: This project builds on unique capabilities of the collaborating labs, including flexible in vitro translation technology for RNA display of trillion-member cyclic peptide libraries (Walport), the discovery of hyperstable photoswitches (Fuchter) and innovations from current ICB CDT students in the Tate group, including the discovery of high-affinity (non-switchable) cd59 ligands using large scale cyclic peptide library screens (Bickel; with Bubeck lab), and incorporation of cell-active photoswitches in small molecule probes (Kounde; with GSK). We thus have in place the sophisticated technologies on which the physical science innovations of this project will build, including validated cyclic peptide libraries, robust photoswitches, and access to a series of model systems on which to test the PhysSci innovations. The project directly addresses the core ICB CDT remit, including molecular interactions (protein/ligand, protein/protein) and incorporation of novel devices into multiscale biological frameworks, with significant future applications in both bioscience and synthetic biology.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金